Semax

Also known as: ACTH(4-7)-Pro-Gly-Pro

Evidence Tier B-Cmed-high riskintermediatenot approved

ACTH fragment analogue with preclinical neurotrophic signaling and limited clinical stroke/cognition data.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

Not Approved

This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.

Overview

Semax is an ACTH fragment analogue (ACTH(4-7) + Pro-Gly-Pro motif). Preclinical studies show increased BDNF expression in ischemia models. Human clinical use reports exist in stroke contexts with multi-mg daily intranasal dosing. FDA flagged semax in compounding safety context citing immunogenicity/impurity concerns and limited safety info for proposed routes. Not FDA-approved.

Research Details

Mechanism of Action

Preclinical neurotrophic signaling including BDNF upregulation; modulation of neurotransmission and neurotrophic pathways proposed.

Study Dose Range

Human stroke studies: multi-mg daily intranasal dosing. Animal: intranasal dosing with gene expression changes within hours.

Administration Routes

intranasal

Onset / Timeline

Gene expression changes within hours (animal); clinical stroke outcomes are longer-horizon.

Expected Effects

Neurotrophic signaling; cognitive/neuroprotection narratives from Russian/EE clinical literature.

Adverse Effects

Immunogenicity/impurity concerns (FDA); limited Western safety framing.

Contraindications

No established label.

Interaction Notes

Unknown; avoid claiming synergy with SSRIs/benzodiazepines without data.

Related Goals

Cognitive & NeuroprotectionAnxiety & Mood

Known Interactions

caution with Selank

FDA notes limited safety-related information and compounding immunogenicity/impurity concerns for both.

caution with DSIP

CNS-active peptide combination; limited human safety basis.

caution with Cerebrolysin

Both are CNS-active experimental agents. Combination claims are stronger than the human safety evidence.

caution with NSI-189

Mechanistically interesting but human combination data are weak; conservative caution.

Available From

Amino Club

consumer RUO · COA: product page COA viewer

10 mg / 20 mg (variant-dependent) · variant-dependent on product page

Consumer RUO; review product details carefully

A dedicated Semax page is available, so users can go straight to the relevant listing.

USVisit Vendor

QC: third-party purity testing; product-level COA on page

Shipping: US/ROW (verify current policy) · affiliate: public program

Read this before you compare products

How to Reconstitute Peptides

A practical guide to reconstitution math, handling basics, and the mistakes that create contamination or dosing problems.

Read guide

Frequently Compared

Selank

Tuftsin analogue peptide with anxiolytic/nootropic research and limited clinical GAD data.

Tier B-C

DSIP

Sleep-related peptide with human IV infusion studies showing sleep pressure effects. Mechanism uncertain.

Tier B

Oxytocin

Well-studied neuropeptide with extensive human research on social/emotional processing. Prescription product.

Tier A

Dihexa

Preclinical procognitive/synaptogenic compound acting via HGF/c-Met axis. No long-term human safety data.

Tier C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.